Dr Artur Jurczyszyn, MD PhD - Department of Hematology University Hospital

Dr Artur Jurczyszyn

MD PhD

Department of Hematology University Hospital

Poland

Dr Artur Jurczyszyn, MD PhD - Department of Hematology University Hospital

Dr Artur Jurczyszyn

MD PhD
Introduction

Primary Affiliation: Department of Hematology University Hospital - Poland

Metrics

14

Publications

390

Profile Views

64

Reads

24

PubMed Central Citations

Publications

14Publications

64Reads

24PubMed Central Citations

A fatal case of acquired hemophagocytic lymphohistiocytosis (macrophage activation syndrome) in the initial course of dermatomyositis with anti-Jo-1 antibody.

Int J Rheum Dis 2017 Dec 30;20(12):2171-2174. Epub 2013 Sep 30.

Second Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.

View Article
December 2017
3 Reads
1.77 Impact Factor

Bortezomib for the treatment of multiple myeloma.

Expert Rev Hematol 2014 Apr;7(2):173-85

Department of Hematology, Community Hospital in Chorzow, Chorzow, Poland.

View Article
April 2014
2 Reads
1 PubMed Central Citation(source)

Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era.

Cancer Epidemiol Biomarkers Prev 2014 Apr 12;23(4):670-4. Epub 2014 Feb 12.

Authors' Affiliations: Genomic Epidemiology Group, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Hematology, Cracow University Hospital, Cracow; Medical University of Łodz; Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; Rzeszow Regional Hospital, Rzeszow; Holycross Cancer Center, Kielce, Poland; Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; Morales Meseguer General University Hospital, Murcia; University Hospital of Salamanca, Salamanca; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; Hematology Department, Virgen de las Nieves University Hospital, Granada; IDIBELL-Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; Semmelweis University, Budapest, Hungary; Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; Department of Biology, University of Pisa, Pisa, Italy; Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; Organ Center, Hospital of Southern Jutland, Aabenraa; Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; National Research Centre for the Working Environment, Copenhagen; Roskilde Hospital, Copenhagen University, Roskilde, Denmark; Life and Health Sciences Research Institute, University of Minho, Braga; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.

View Article
April 2014
14 Reads
2 PubMed Central Citations(source)
4.12 Impact Factor

Transient cortical blindness after coronary artery angiography.

Postepy Kardiol Interwencyjnej 2013 21;9(1):105-8. Epub 2013 Mar 21.

1 Department of Cardiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland.

View Article
February 2014
0.07 Impact Factor

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.

Hematol Oncol 2013 Mar 6;31(1):41-8. Epub 2012 Jun 6.

Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.

View Article
March 2013
3 Reads
2 PubMed Central Citations(source)
3.08 Impact Factor

[Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].

Przegl Lek 2011 ;68(6):320-5

Klinika Hematologii Szpital Uniwersytecki w Krakowie.

View Article
March 2012
7 Reads

[Waldenström's macroglobulinemia--the experts opinion about new therapeutic possibilities and response criteria].

Pol Arch Med Wewn 2004 Sep;112(3):1113-21

Klinika Hematologii CM UJ, Kraków.

View Article
September 2004
1 Read

[Hepatocyte growth factor: from diagnosis to clinical application].

Przegl Lek 2003 ;60(6):425-34

Katedra i Klinika Hematologii, Collegium Medicum Uniwersytet Jagielloński w Krakowie.

View Article
May 2004
1 Read

[Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].

Przegl Lek 2003 ;60(8):542-7

Katedra i Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego, 31-501 Kraków, ul. Kopernika 17.

View Article
May 2004
2 Reads